Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
November 6, 2024
We are revolutionizing cancer treatment by activating
the untapped power of the innate
immune system to eradicate tumors. Our novel and proprietary technology binds NK cells and other innate immune cells directly to tumor cells, allowing for tumor destruction.
This approach is versatile and scalable.
Our approach is differentiated and IP-protected, and has the promise to help patients who
have already undergone earlier lines of therapy that proved to be unsuccessful.
We have entered select partnerships with esteemed pharmaceutical companies who share our passion for bringing change to the treatment of cancer.
We trust that we can help those who have been
left behind due to a lack of efficacy or unpredictable
toxicity with traditional therapies. Clinical results already
light the way for patients suffering from multiple types of
cancer. Studies have demonstrated good safety and efficacy data including unprecedented ORR in patients with relapsed/refractory HL.
Now is your chance to be part of the next revolution in cancer treatment. Join us.
PUBLICATIONS AND POSTERS
clinical literature.
PIPELINE
ICE® (innate cell engager)
molecules and combination products.
INVESTORS
cancer treatment.
HL=Hodgkin Lymphoma; IP=intellectual property; NK=natural killer; ORR=objective response rate.